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free survival (DFS) and OS rates were calculated using the 
Kaplan-Meier method. Multivariate analyses were performed 
using the Cox proportional hazards model. 
Results: The median follow-up for all patients and surviving 
patients was 25 months (range, 3–75 months) and 28 months 
(range, 15–75 months), respectively. Post-treatment MRI 
images were taken within a median of 3.2 months (range, 
2.8–4.1 months) after the completion of CRT. At post-
treatment MRI, 41 patients (93%) exhibited a complete 
response. The mean pretreatment and posttreatment 
ADCmean were 0.882±0.096 × 10-3 mm2/sec, 1.159±0.168 × 
10-3 mm2/sec, respectively. Median percent ADC change was 
33.7% (5.0 – 70.0%). The analyses identified pretreatment 
ADCmean of the primary tumor cutoff values of 0.878× 10-3 
mm2/sec for recurrence (area under the curve [AUC] = 0.818, 
p<0.001; 95% CI, 0.690–0.946, sensitivity 86.4%, specificity 
72.7%), posttreatment ADCmean of the primary tumor cutoff 
values of 1.132 × 10-3 mm2/sec for recurrence (AUC = 0.810, 
p<0.001; 95% CI, 0.684–0.936, sensitivity 77.3%, specificity 
72.7%), ADC change cutoff values of 32.8% for recurrence 
(AUC = 0.810, p<0.001; 95% CI, 0.683–0.937, sensitivity 77.3%, 
specificity 68.2%). In a multivariate analysis, pelvic lymph 
node metastasis and pretreatment ADCmean were significant 
prognostic factors for both OS and DFS. Additionally, ADC 
change between pretreatment and posttreatment DW-MRI 
was significant factor for OS. 
 
Conclusion: Our findings provide evidence that 
posttreatment low ADCmean of the primary tumor is a useful 
clinical prognostic biomarker for recurrence and survival in 
patients with cervical cancer. 
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Purpose or Objective: Radiation therapy on the pelvic region 
in women may induce disturbing vaginal irritation impacting 
on patients quality of life. We tested a hyaluronic acid based 
vaginal washing (Justgin) in the prevention of vaginal 
mucositis in patients treated with external beam radiation 
therapy for pelvic neoplasms. 
 
Material and Methods: Fifty eight female patients affected 
by uterine tumors and undergoing radiation therapy on the 
pelvic region were considered for the study. Median age was 
58. Twenty eight patients were affected by endometrial 
cancer, while 30 were affected by cervical cancer. Radiation 
therapy was delivered by 6 MV X ray of a linear accelerator 
with 4 fields 3D conformal radiation therapy with a dose of 
45-50.4 Gy in 25-28 daily 1.8 Gy fractions. Group A (28 
patients) used Justgin every other day, and 30 patients 
(group B) did not use any prophylactic therapy. Patients were 
visited and interviewed about vaginal discomfort or 
symptoms every week. 
 
Results: At the end of radiation therapy 13/28 patients of 
group A and 27/30 of group B, developed vaginal toxicity of 
any grade (p=0.0005). Overall, however the toxicity was mild 
or moderate in all patients. 
 
Conclusion: Our study suggests that a vaginal washing with 
hyaluronic acid (Justgin) can reduce the incidence of the 
vaginal acute symptoms induced by external beam irradiation 
in women affected by uterine cancer. 
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Purpose or Objective: Endometrial cancer (EC) is the leading 
malignant tumour occurring in the female genital tract. 
miRNAs are small non-coding RNAs that have a broad impact 
on cancer progression. The aim of our study was to define 
tissue miRNA-205 expression levels, which could potentially 
serve as a prognostic marker in EC. We investigated miRNA-
205 profiles in regard to clinicopathological characteristics of 
patients treated with adjuvant radiotherapy from 2002 until 
2014. 
 
Material and Methods: Expression profiling of miRNA-205 was 
performed in EC tissues from patients who were submitted to 
adjuvant radiotherapy after hysterectomy, according to the 
International Federation of Gynecology and Obstetrics (FIGO) 
guidelines. 90 patients were included in the study. The 
median follow-up period was 46 months (min.2 
months;max.119 months). We analyzed the paraffin-
embedded tissue samples and identified the areas of EC. We 
extracted total RNA from 90 EC samples. The reference group 
was constituted by 10 paraffin-embedded healthy 
endometrial tissue samples. Spectrophotometric assessment 
of the total RNA concentration was performed. cDNA was 
synthesized from total RNA with high capacity cDNA synthesis 
kit and miRNA-specific primers (miR-205 and internal control 
RNU6b). The expression of the miRNA-205 was determined 
using real-time quantitive PCR. The expression level of 
miRNA-205 was calculated by ∆CT values based on the 
internal control and plotted as relative value (RV). 
 
Results: Our results indicate that the expression of miRNA-
205 was significantly higher in EC samples (p=0,000158). The 
expression of miRNA-205 was differentiated considering 
different grading levels. The lowest miRNA-205 expression 
was observed in grade 3 (p=0,02). There was no correlation 
between FIGO stages of EC and miRNA-205 expression 
(p=0,23). When we divided patients into two subgroups: 
advanced EC (III, IV FIGO) and non-advanced EC (I,II FIGO) it 
turned out that the expression levels of miRNA-205 were 
significantly lower in the advanced EC patients group 
(p<0,045). The miRNA-205 expression was lower when there 
was over 50% invasion of the myometrium (p<0,038). Kaplan-
Meier survival curves were generated to examine the 
relationship between the expression levels of miRNA-205 and 
patient’s survival rate. Its analysis revealed that high levels 
of miRNA-205 are associated with longer survival (fig.1).  
 
 
Conclusion: Increased miRNA-205 expression is a positive 
prognostic factor. Lower levels of miRNA-205 are 
characteristic of more advanced stages of EC. 
 
 
 
